2008年-2009年铜绿假单胞菌的临床分布及耐药性分析

Clinical Distribution of Pseudomonas Aeruginosa and Analysis of Drug Resistance from 2008 to 2009

目的分析2008年-2009年临床分离251株铜绿假单胞菌的临床分布及对抗菌药物的耐药状况,为临床合理用药提供依据。方法纸片扩散法(Kirby-Baure)测定该菌对阿米卡星、亚胺培南等10多种广谱抗菌药物的耐药性。判断标准参照2007年版CLSI文件。所得数据用WHONET5.3软件进行统计分析。结果 2年共分离铜绿假单胞菌251株,以呼吸道标本分离株为主占63.7%,且临床分布于ICU、呼吸内科和肾脏内科等科室。2009年铜绿假单胞菌对多数抗菌药物耐药率略高于2008年。对阿米卡星耐药率最低(6.8%),其次是亚胺培南(13.5%)、美罗培南(15.2%)、头孢他啶(15.5%)、头孢吡肟(19.6%)、氨曲南(23.0%),其它抗菌药物的耐药率大于36.1%。结论铜绿假单胞菌是医院感染的重要病原菌,应加强耐药性监测,为指导临床合理选用抗菌药物提供依据。

Objective to investigate the clinical distribution and analyze of the antibiotic resistance of 251 strains of pseudomonas aeruginosa providing the basis for clinical reasonable medication from 2008 to 2009.Methods We use Kirby-Baure method to test the resistance of pseudomonas aeruginosa to amikacin,imipenem and other 10 kinds of broad-spectrum antibiotics.It defines the standard according to CLSI document of 2007 edition.The data are analyzed by the software of WHONET5.3.Results A total of 251 strains of pseudomonas aeruginosa were isolated during these two years;specimen are mainly from respiratory tract（63.7%）,which clinical distribute in ICU、respiration and nephrology.The rate of resistance of pseudomonas aeruginosa to most antibiotics in 2009 is higher than.Among the antibiotics shows lowest resistance rate（6.8%） to amikacin,followed by imipenem（13.5%）,meropenem（15.2%）,ceftazidime（15.5%）,cefepime（19.6%）,azereonam（23.0%）;The resistance rates of other antimicrobial agents were above 36.1%.Conclusions Pseudomonas aeruginosa is the main pathogen of nosocomial infections which need to strengthen resistance monitor,providing basis for choosing clinical antibiotics reasonably to clinical departments.